Conversely, our group demonstrated that the tumor-targeted inhibition of TLR2 represents a key strategy in malignancy such as breast cancer, where high TLR2 expression correlates with poor prognosis and chemoresistance. The gene discussed is TLR2; the disease is breast carcinoma.